Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
Journal of Gastroenterology
|
May 12, 2009
Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer
Takako Eguchi Nakajima, Yasuhide Yamada, Tetsutaro Hamano, et al.
Journal of Cancer Research and Clinical Oncology
|
August 21, 2009
Adipocytokines and squamous cell carcinoma of the esophagus
Takako Eguchi Nakajima, Yasuhide Yamada, Tetsutaro Hamano, et al.
BMC Cancer
|
August 2, 2018
An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023
Tadahiro Shoji, Shinichi Komiyama, Junzo Kigawa, et al.
Biochemical and Biophysical Research Communications
|
March 11, 2008
Increased expression of highly sulfated keratan sulfate synthesized in malignant astrocytic tumors
Yukinari Kato, Norihito Hayatsu, Mika Kato Kaneko, et al.
The Journal of Obstetrics and Gynaecology Research
|
March 1, 2023
Comparison of older and younger patients with ovarian cancer: A post hoc study (JGOG3016-A3) of the treatment strength and prognostic outcomes of conventional or dose-dense chemotherapy
Yoshio Itani, Hitomi Sakai, Tetsutaro Hamano, et al.
Japanese Journal of Clinical Oncology
|
October 13, 2010
A randomized Phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer
Keiichi Fujiwara, Eriko Aotani, Tetsutaro Hamano, et al.
Breast Cancer Research and Treatment
|
April 15, 2014
Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression
Masashi Ando, Hideko Yamauchi, Kenjiro Aogi, et al.
Scientific Reports
|
October 29, 2020
Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma
Akira Yabuno, Hirokazu Matsushita, Tetsutaro Hamano, et al.
Cancers
|
December 11, 2025
No Correlation Between Proteinuria and Renal Function in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: ARISE Study
Kazuomi Ueshima, Naoshi Nishida, Satoru Hagiwara, et al.
BMC Cancer
|
March 12, 2025
Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma
Yoshihisa Kodama, Kazuomi Ueshima, Michihisa Moriguchi, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
Journal of Gastroenterology
|
May 12, 2009
Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer
Takako Eguchi Nakajima, Yasuhide Yamada, Tetsutaro Hamano, et al.
Journal of Cancer Research and Clinical Oncology
|
August 21, 2009
Adipocytokines and squamous cell carcinoma of the esophagus
Takako Eguchi Nakajima, Yasuhide Yamada, Tetsutaro Hamano, et al.
BMC Cancer
|
August 2, 2018
An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023
Tadahiro Shoji, Shinichi Komiyama, Junzo Kigawa, et al.
Biochemical and Biophysical Research Communications
|
March 11, 2008
Increased expression of highly sulfated keratan sulfate synthesized in malignant astrocytic tumors
Yukinari Kato, Norihito Hayatsu, Mika Kato Kaneko, et al.
The Journal of Obstetrics and Gynaecology Research
|
March 1, 2023
Comparison of older and younger patients with ovarian cancer: A post hoc study (JGOG3016-A3) of the treatment strength and prognostic outcomes of conventional or dose-dense chemotherapy
Yoshio Itani, Hitomi Sakai, Tetsutaro Hamano, et al.
Japanese Journal of Clinical Oncology
|
October 13, 2010
A randomized Phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer
Keiichi Fujiwara, Eriko Aotani, Tetsutaro Hamano, et al.
Breast Cancer Research and Treatment
|
April 15, 2014
Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression
Masashi Ando, Hideko Yamauchi, Kenjiro Aogi, et al.
Scientific Reports
|
October 29, 2020
Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma
Akira Yabuno, Hirokazu Matsushita, Tetsutaro Hamano, et al.
Cancers
|
December 11, 2025
No Correlation Between Proteinuria and Renal Function in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: ARISE Study
Kazuomi Ueshima, Naoshi Nishida, Satoru Hagiwara, et al.
BMC Cancer
|
March 12, 2025
Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma
Yoshihisa Kodama, Kazuomi Ueshima, Michihisa Moriguchi, et al.
Page
of 3